Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a ...
The New York Times

Is This Lip Mask Worth the Hype? We Think So.

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Hannah Frye Hannah Frye is ...